drugset / Trial / NCT04486378

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

NCT04486378 ↗

Phase 2 Active not recruiting 327 enrolled BioNTech SE Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

Timeline

Start
2021-03-08
Primary completion
2026-11
Completion
2030-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Autogene cevumeran Messenger RNA (mRNA) — Intravenous

Indications